1013-78-1

Basic information

• Product Name: 1-(2,4-DICHLOROPHENYL)PIPERAZINE
• Synonyms: 1-(2,4-DICHLOROPHENYL)PIPERAZINE;N-(2,4-Dichlorophenyl)piperazine
• CAS NO: 1013-78-1
• Molecular Formula: C₁₀H₁₂Cl₂N₂
• Molecular Weight: 231.12168
• Mol File: 1013-78-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2,4-DICHLOROPHENYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,4-DICHLOROPHENYL)PIPERAZINE(1013-78-1)
• EPA Substance Registry System: 1-(2,4-DICHLOROPHENYL)PIPERAZINE(1013-78-1)

Safety Data

• Hazardous Substances Data: 1013-78-1(Hazardous Substances Data)

Usage

Description

1-(2,4-Dichlorophenyl)piperazine, with the molecular formula C10H12Cl2N2, is a chemical compound belonging to the class of piperazine derivatives. It is characterized by its serotonergic receptor antagonist activity, which allows it to modulate serotonin levels in the brain. 1-(2,4-DICHLOROPHENYL)PIPERAZINE has been investigated for its potential use in the development of antipsychotic and antidepressant medications, as well as its psychoactive properties, including stimulant and hallucinogenic effects observed in animal studies. However, its production and use are subject to regulation due to concerns about its potential for misuse.

Uses

Used in Pharmaceutical Synthesis:
1-(2,4-Dichlorophenyl)piperazine is used as a key intermediate in the synthesis of various pharmaceuticals, particularly those aimed at treating mental health disorders. Its role in modulating serotonin levels makes it a valuable component in the development of antipsychotic and antidepressant medications.
Used in Psychoactive Drug Research:
In the field of psychoactive drug research, 1-(2,4-Dichlorophenyl)piperazine is utilized as a subject of study for its potential as a psychoactive substance. Its stimulant and hallucinogenic effects, as demonstrated in animal studies, contribute to the ongoing investigation of its properties and possible applications in this area.
Used in Serotonin Receptor Research:
1-(2,4-Dichlorophenyl)piperazine is also used in the research of serotonergic receptors due to its antagonistic activity. Understanding its interaction with these receptors can provide insights into the development of new treatments for a range of conditions related to serotonin imbalances.
Regulated Application:
Due to its psychoactive properties and potential for misuse, the use and production of 1-(2,4-Dichlorophenyl)piperazine are regulated in various jurisdictions. This ensures that its application remains focused on legitimate medical and research purposes, minimizing the risk of diversion for illicit use.

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 110-85-0 piperazine 
• 1435-48-9 1,3-dichloro-4-fluorobenzene 
• 1193-72-2 1-bromo-2,4-dichlorobenzene 
• 3375-31-3 palladium diacetate 
• 865-48-5 sodium t-butanolate 

Downstream Products

• 945423-09-6 2-chloro-1-[4-(2,4-dichloro-phenyl)-piperazin-1-yl]-ethanone 

Relevant articles and documents

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators

Positive allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) is regarded as a potential novel treatment for schizophrenic patients. Herein we report the synthesis and SAR of 4-aryl piperazine and piperidine amides as potent mGluR5 positive allosteric modulators (PAMs). Several analogs have excellent activity and desired drug-like properties. Compound 2b was further characterized as a PAM using several in vitro experiments, and produced robust activity in several preclinical animal models.

Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: Inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors

The synthesis, pharmacological evaluation, and structure - activity relationships (SARs) of a series of novel arylalkylpiperazines structurally related to BP897 (3) are described. In binding studies, the new derivatives were tested against a panel of dopamine, serotonin, and noradrenaline receptor subtypes. Focusing mainly on dopamine D3 receptors, SAR studies brought to light a number of structural features required for high receptor affinity and selectivity. Several heteroaromatic systems were explored for their dopamine receptor affinities, and combinations of synthesis, biology, and molecular modeling, were used to identify novel structural leads for the development of potent and selective D3 receptor ligands. Introduction of an indole ring linked to a dichlorophenylpiperazine system provided two of the most potent and selective ligands known to date (D 3 receptor affinity in the picomolar range). The intrinsic pharmacological properties of a subset of potent D3 receptor ligands were also assessed in [35S]-GTPγS binding assays. Evidence from animal studies, in particular, has highlighted the dopaminergic system's role in how environmental stimuli induce drug-seeking behavior. We therefore tested two novel D3 receptor partial agonists and a potent D 3-selective antagonist in vivo for their effect in the cocaine-seeking behavior induced by reintroduction of cocaine-associated stimuli after a long period of abstinence, and without any further cocaine. Compound 5g, a nonselective partial D3 receptor agonist with a pharmacological profile similar to 3, and 5p, a potent and selective D 3 antagonist, reduced the number of active lever presses induced by reintroduction of cocaine-associated stimuli. However, 5q, a highly potent and selective D3 partial agonist, did not have any effect on cocaine-seeking behavior. Although brain uptake studies are needed to establish whether the compounds achieve brain concentrations comparable to those active in vitro on the D3 receptor, our experiments suggest that antagonism at D2 receptors might significantly contribute to the reduction of cocaine craving by partial D3 agonists.